Affimed (NASDAQ:AFMD) Short Interest Down 9.4% in August

Affimed (NASDAQ:AFMD) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 718,200 shares, a decrease of 9.4% from the August 15th total of 792,600 shares. Based on an average daily trading volume, of 181,600 shares, the short-interest ratio is currently 4.0 days. Currently, 5.5% of the shares of the stock are short sold.

Affimed Price Performance

NASDAQ:AFMD opened at $4.07 on Wednesday. The stock’s 50-day moving average is $4.48 and its 200-day moving average is $5.16. Affimed has a 1-year low of $2.23 and a 1-year high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71.

Hedge Funds Weigh In On Affimed

Several large investors have recently modified their holdings of AFMD. BNP Paribas Financial Markets raised its position in Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares during the last quarter. Vestal Point Capital LP acquired a new stake in shares of Affimed in the fourth quarter valued at about $341,000. Finally, Choreo LLC bought a new position in shares of Affimed during the second quarter worth about $54,000. Institutional investors own 30.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Laidlaw boosted their target price on shares of Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Affimed in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Affimed has an average rating of “Moderate Buy” and an average target price of $32.50.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.